Interview with the Innovators

Interview with the Innovators

Emerging Treatments in Multiple Myeloma
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, talk about the emerging treatments for MM, including monoclonal antibodies, 2nd-generation protease inhibitors, and targeted therapies. These changes pose challenges to healthcare providers struggling to keep up with these changes, but this is good news for patients with expanding treatment options.

Current Standard of Care for Patients with Multiple Myeloma Based on Their Eligibility for Autologous Stem-Cell Transplant
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.

Standard of Care Therapy for Transplant Eligible Patients with Multiple Myeloma Based on Risk Stratification
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C discuss their approach to the care of transplant-eligible patients with multiple myeloma, particularly based on the patients' risk stratification, as well as poor-prognosis cytogenetics including those with (4,14) translocation.

An Interview with Donna Moore Wilson, RN, MSN, CBCN, of the Virginia Cancer Patient Navigator Network


The Biden Cancer Initiative builds on the momentum of the Obama-Biden administration’s Cancer Moonshot effort.

Overcoming Challenges to Molecular Biomarker Testing
Drs. Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges in biomarker testing—tissue stewardship and complexity of biomarker tests and results—and ways to overcome these challenges—improved communication among all members of the cancer care team and simplification of biomarker test results to focus on actionable biomarkers.

Impact of Reimbursement for Biomarker Testing on Clinical Practice
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”

Reimbursement Challenges and Solutions with Molecular Biomarker Testing
Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.

Identifying and Solving Top Challenges to Oncology Biomarker Testing
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.

Page 8 of 12

Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country